Decision tree

Hyundai Offers Complimentary Charger, Installation Assistance for EV Customers

Retrieved on: 
Thursday, September 21, 2023

Hyundai EV Customers Receive Complimentary ChargePoint® Home Flex Level 2 EV Charger and up to $600 Off Installation Using the Hyundai Home Marketplace.

Key Points: 
  • Hyundai EV Customers Receive Complimentary ChargePoint® Home Flex Level 2 EV Charger and up to $600 Off Installation Using the Hyundai Home Marketplace.
  • The Hyundai Home Marketplace is a one-stop shop for Hyundai EV customers' home electrification needs.
  • On the Marketplace, customers can arrange for the delivery and installation of their complimentary home EV charger, as well as purchase solar panels and home energy storage systems.
  • Installation services are provided by third-party electricians sourced through the Hyundai Home service and contracted by customers for their projects.

Vegas Bot AI starts Presale with the bang, users can secure revenue with their advanced AI-powered strategies

Retrieved on: 
Thursday, March 23, 2023

AIML or Artificial Intelligence Markup Language is a markup language that Chatbot AI uses to develop rule-based Chatbot AI.

Key Points: 
  • AIML or Artificial Intelligence Markup Language is a markup language that Chatbot AI uses to develop rule-based Chatbot AI.
  • Vegas Bot AI - Offering a New Way of Chatbot AI:
    Vegas Bot AI aims to provide businesses with a disruptive and dynamic Chatbot AI technology that can keep users engaged, in turn increasing customer satisfaction.
  • The Presale of Vegas Bot AI Tokens:
    Vegas Bot AI is proud to announce that it is moving towards presale of the Vegas Bot AI Token Launch.
  • Vegas Bot AI envisions a future where Chatbot AI technology is increasingly adopted by businesses worldwide.

PreludeDx™ DCISionRT® Data Presented in Spotlight Presentation at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 9, 2022

LAGUNA HILLS, Calif., Dec. 9, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior recurrence risk stratification and radiation therapy (RT) benefit prediction compared to commonly used clinicopathologic (CP) features. The data was presented in a spotlight presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • The data was presented in a spotlight presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).
  • Whereas DCISionRT Low Risk patients, which included about one-third of CP High-Risk patients, had no significant RT benefit, representing a true low risk group.
  • PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide.
  • Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision.

PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, November 16, 2022

"We remain committed to continual improvement of personalized medicine for early-stage breast cancer patients and their clinicians."

Key Points: 
  • "We remain committed to continual improvement of personalized medicine for early-stage breast cancer patients and their clinicians."
  • Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue.
  • PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide.
  • Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision.

PreludeDx™ Presents DCISionRT® Data in Oral Presentation at the American Society for Radiation Oncology Annual Meeting

Retrieved on: 
Tuesday, October 25, 2022

LAGUNA HILLS, Calif., Oct. 25, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior risk and RT benefit prediction compared to common clinicopathologic features. The data was presented in an oral presentation at the 64th Annual American Society for Radiation Oncology (ASTRO) Meeting, held on October 23 – 26, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

Key Points: 
  • The data was presented in an oral presentation at the 64th Annual American Society for Radiation Oncology (ASTRO) Meeting, held on October 23 26, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
  • "It is important to follow the clinical evidence when making the best treatment decisions with our patients.
  • "DCISionRT provides unique game-changing information to enable physicians and DCIS patients to confidently make a personalized treatment decision," said Dan Forche, President and CEO of PreludeDx.
  • DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit.

Aerolib Healthcare Solutions has launched the Aerolib Denials and Appeals Portal

Retrieved on: 
Friday, April 15, 2022

FRISCO, Texas, April 15, 2022 /PRNewswire-PRWeb/ -- Aerolib Healthcare Solutions has launched the Aerolib Denials and Appeals Portal. The Tool enables hospitals with an Appeal Strength score and autogenerating an email and print ready Appeal letter in response to a denial. Hospitals are facing an increasing burden of denials for medical necessity. The Aerolib tool provides a prescreening score and appeal strength score with recommendations for appeals. Preview Appeal button will autogenerate the Appeal letter. This is the power of the management tool where it writes an appeal letter with clinical information and medico-legal discussion of why this case should be appealed with the justification and strength of appeal.

Key Points: 
  • FRISCO, Texas, April 15, 2022 /PRNewswire-PRWeb/ -- Aerolib Healthcare Solutions has launched the Aerolib Denials and Appeals Portal.
  • The Aerolib tool provides a prescreening score and appeal strength score with recommendations for appeals.
  • The Aerolib Denials and Appeals Management software uses Aerolib AI algorithm to predict postoperative complications and readmissions with multiple risk factors that have been analyzed using simple logistic regression and multivariate logistic regression.
  • AEROLIB comprises of Aerolib Healthcare Solutions LLC, Aerolib Ventures LLC and Aerolib Insights LLC